Moderna says FDA needs more time to review its vaccine for teens

Moderna stated the Meals and Drug Administration will want extra time to finish its evaluation of the biotech firm’s Covid-19 vaccine for kids ages 12 to 17.

The company is wanting particularly on the threat of myocarditis in youngsters, Moderna stated in a press release Sunday, and the evaluation might not be accomplished earlier than January 2022. Myocarditis is the irritation of the guts muscle.

“The corporate is absolutely dedicated to working intently with the FDA to assist their evaluation and is grateful to the FDA for his or her diligence,” Moderna stated.

Moderna additionally stated it can delay submitting a request for emergency use authorization for a smaller dose of the vaccine for youthful youngsters ages 6 to 11 whereas the FDA completes its evaluation.

Moderna stated on Could 25 its Covid vaccine was 100% efficient in a research of 12-to-17-year-olds. The corporate then utilized to broaden the emergency use of its vaccine for adolescents in June.

Subscribe to CNBC on YouTube.

Source link

Related posts

Goldman cuts GDP forecast after Sen. Manchin says he won’t support Biden’s ‘Build Back Better’ plan

WDC TV Staff

Here are Thursday's biggest analyst calls of the day: Disney, Penn, Chevron, Shopify & more

WDC TV Staff

Krispy Kreme returns to a very different public market

WDC TV Staff